93 related articles for article (PubMed ID: 19902153)
21. Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit.
Croda J; Croda MG; Neves A; De Sousa dos Santos S
Crit Care Med; 2009 May; 37(5):1605-11. PubMed ID: 19325488
[TBL] [Abstract][Full Text] [Related]
22. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy.
Scott Sutton S; Magagnoli J; Hardin JW
Pharmacotherapy; 2016 Apr; 36(4):385-401. PubMed ID: 26923931
[TBL] [Abstract][Full Text] [Related]
23. Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data.
Clements M; Law M; Pedersen C; Kaldor J;
HIV Med; 2003 Oct; 4(4):332-7. PubMed ID: 14525545
[TBL] [Abstract][Full Text] [Related]
24. 2010 guidelines for antiretroviral treatment of HIV from the International AIDS Society-USA Panel.
Bucher HC; Wolbers M; Porter K
JAMA; 2010 Nov; 304(17):1897; author reply 1897-8. PubMed ID: 21045094
[No Abstract] [Full Text] [Related]
25. A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NA-ACCORD and CCASAnet clinical cohorts.
Althoff KN; Rebeiro PF; Hanna DB; Padgett D; Horberg MA; Grinsztejn B; Abraham AG; Hogg R; Gill MJ; Wolff MJ; Mayor A; Rachlis A; Williams C; Sterling TR; Kitahata MM; Buchacz K; Thorne JE; Cesar C; Cordero FM; Rourke SB; Sierra-Madero J; Pape JW; Cahn P; McGowan C;
J Int AIDS Soc; 2016; 19(1):20707. PubMed ID: 27049052
[TBL] [Abstract][Full Text] [Related]
26. Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US.
Antiretroviral Therapy Cohort Collaboration (ART-CC)
Antivir Ther; 2015; 20(1):21-8. PubMed ID: 24675571
[TBL] [Abstract][Full Text] [Related]
27. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
[TBL] [Abstract][Full Text] [Related]
28. When to start, when to STI (or, groping for the golden moment).
Mascolini M
IAPAC Mon; 2001 Apr; 7(4):114-7, 120-31. PubMed ID: 11700605
[No Abstract] [Full Text] [Related]
29. If we can't get what we want, can we get what we need? optimizing use of antiretroviral therapy in the current era.
Baker JV; Henry K
Ann Intern Med; 2011 Apr; 154(8):563-5. PubMed ID: 21502654
[No Abstract] [Full Text] [Related]
30. Should the CD4 threshold for starting ART be raised?
Wood R; Lawn SD
Lancet; 2009 Apr; 373(9672):1314-6. PubMed ID: 19361856
[No Abstract] [Full Text] [Related]
31. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death.
Kaufmann GR; Elzi L; Weber R; Furrer H; Giulieri S; Vernazza P; Bernasconi E; Hirschel B; Battegay M;
AIDS; 2011 Feb; 25(4):441-51. PubMed ID: 21206265
[TBL] [Abstract][Full Text] [Related]
32. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort.
Matheron S; Pueyo S; Damond F; Simon F; Leprêtre A; Campa P; Salamon R; Chêne G; Brun-Vezinet F;
AIDS; 2003 Dec; 17(18):2593-601. PubMed ID: 14685053
[TBL] [Abstract][Full Text] [Related]
34. Timing of antiretroviral drugs during tuberculosis therapy.
Kadhiravan T
N Engl J Med; 2010 Jun; 362(22):2138; author reply 2138-9. PubMed ID: 20527060
[No Abstract] [Full Text] [Related]
35. Body mass index and early CD4 T-cell recovery among adults initiating antiretroviral therapy in North America, 1998-2010.
Koethe JR; Jenkins CA; Lau B; Shepherd BE; Silverberg MJ; Brown TT; Blashill AJ; Anema A; Willig A; Stinnette S; Napravnik S; Gill J; Crane HM; Sterling TR;
HIV Med; 2015 Oct; 16(9):572-7. PubMed ID: 25960080
[TBL] [Abstract][Full Text] [Related]
36. Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality?
Boulle A; Clayden P; Cohen K; Cohen T; Conradie F; Dong K; Geffen N; Grimwood A; Hurtado R; Kenyon C; Lawn S; Maartens G; Meintjes G; Mendelson M; Murray M; Rangaka M; Sanne I; Spencer D; Taljaard J; Variava E; Venter WD; Wilson D
S Afr Med J; 2010 Sep; 100(9):566, 568, 570-1. PubMed ID: 20822639
[No Abstract] [Full Text] [Related]
37. Getting smarter--the toxicity of undertreated HIV infection.
Currier JS; Baden LR
N Engl J Med; 2006 Nov; 355(22):2359-61. PubMed ID: 17135590
[No Abstract] [Full Text] [Related]
38. [What happens when antiretroviral treatment is interrupted in clinical practice?].
Marcos Sánchez F; Albo Castaño I; Joya Seijo D; del Valle Loarte P; Martín Barranco MJ
An Med Interna; 2005 Oct; 22(10):502. PubMed ID: 16411308
[No Abstract] [Full Text] [Related]
39. Selective drug taking during combination antiretroviral therapy.
Lanzafame M; Melotti R; Lattuada E; Boccafoglio F; Concia E; Verlato G; Vento S
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):490-1. PubMed ID: 17353720
[No Abstract] [Full Text] [Related]
40. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children.
Palumbo PE; Raskino C; Fiscus S; Pahwa S; Fowler MG; Spector SA; Englund JA; Baker CJ
JAMA; 1998 Mar; 279(10):756-61. PubMed ID: 9508151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
